BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29079609)

  • 1. Investigation of the international comparability of population-based routine hospital data set derived comorbidity scores for patients with lung cancer.
    Lüchtenborg M; Morris EJA; Tataru D; Coupland VH; Smith A; Milne RL; Te Marvelde L; Baker D; Young J; Turner D; Nishri D; Earle C; Shack L; Gavin A; Fitzpatrick D; Donnelly C; Lin Y; Møller B; Brewster DH; Deas A; Huws DW; White C; Warlow J; Rashbass J; Peake MD
    Thorax; 2018 Apr; 73(4):339-349. PubMed ID: 29079609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Explaining variation in cancer survival between 11 jurisdictions in the International Cancer Benchmarking Partnership: a primary care vignette survey.
    Rose PW; Rubin G; Perera-Salazar R; Almberg SS; Barisic A; Dawes M; Grunfeld E; Hart N; Neal RD; Pirotta M; Sisler J; Konrad G; Toftegaard BS; Thulesius H; Vedsted P; Young J; Hamilton W; ;
    BMJ Open; 2015 May; 5(5):e007212. PubMed ID: 26017370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based study.
    McPhail S; Swann R; Johnson SA; Barclay ME; Abd Elkader H; Alvi R; Barisic A; Bucher O; Clark GRC; Creighton N; Danckert B; Denny CA; Donnelly DW; Dowden JJ; Finn N; Fox CR; Fung S; Gavin AT; Gomez Navas E; Habbous S; Han J; Huws DW; Jackson CGCA; Jensen H; Kaposhi B; Kumar SE; Little AL; Lu S; McClure CA; Møller B; Musto G; Nilssen Y; Saint-Jacques N; Sarker S; Te Marvelde L; Thomas RS; Thomas RJS; Thomson CS; Woods RR; Zhang B; Lyratzopoulos G;
    Lancet Oncol; 2022 May; 23(5):587-600. PubMed ID: 35397210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An investigation of routes to cancer diagnosis in 10 international jurisdictions, as part of the International Cancer Benchmarking Partnership: survey development and implementation.
    Weller D; Vedsted P; Anandan C; Zalounina A; Fourkala EO; Desai R; Liston W; Jensen H; Barisic A; Gavin A; Grunfeld E; Lambe M; Law RJ; Malmberg M; Neal RD; Kalsi J; Turner D; White V; Bomb M; Menon U;
    BMJ Open; 2016 Jul; 6(7):e009641. PubMed ID: 27456325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time intervals and routes to diagnosis for lung cancer in 10 jurisdictions: cross-sectional study findings from the International Cancer Benchmarking Partnership (ICBP).
    Menon U; Vedsted P; Zalounina Falborg A; Jensen H; Harrison S; Reguilon I; Barisic A; Bergin RJ; Brewster DH; Butler J; Brustugun OT; Bucher O; Cairnduff V; Gavin A; Grunfeld E; Harland E; Kalsi J; Knudsen AK; Lambe M; Law RJ; Lin Y; Malmberg M; Turner D; Neal RD; White V; Weller D
    BMJ Open; 2019 Nov; 9(11):e025895. PubMed ID: 31776134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of liver cancer incidence and survival by subtypes across seven high-income countries.
    Rutherford MJ; Arnold M; Bardot A; Ferlay J; De P; Tervonen H; Little A; Bucher O; St Jacques N; Gavin A; Engholm G; Møller B; O'Connell DL; Merrett N; Parkin DM; Bray F; Soerjomataram I
    Int J Cancer; 2021 Dec; 149(12):2020-2031. PubMed ID: 34460109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic routes and time intervals for patients with colorectal cancer in 10 international jurisdictions; findings from a cross-sectional study from the International Cancer Benchmarking Partnership (ICBP).
    Weller D; Menon U; Zalounina Falborg A; Jensen H; Barisic A; Knudsen AK; Bergin RJ; Brewster DH; Cairnduff V; Gavin AT; Grunfeld E; Harland E; Lambe M; Law RJ; Lin Y; Malmberg M; Turner D; Neal RD; White V; Harrison S; Reguilon I; ; Vedsted P
    BMJ Open; 2018 Nov; 8(11):e023870. PubMed ID: 30482749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study.
    McPhail S; Barclay ME; Johnson SA; Swann R; Alvi R; Barisic A; Bucher O; Creighton N; Denny CA; Dewar RA; Donnelly DW; Dowden JJ; Downie L; Finn N; Gavin AT; Habbous S; Huws DW; May L; McClure CA; Møller B; Musto G; Nilssen Y; Saint-Jacques N; Sarker S; Shack L; Tian X; Thomas RJS; Thomson CS; Wang H; Woods RR; You H; Lyratzopoulos G;
    Lancet Oncol; 2024 Mar; 25(3):338-351. PubMed ID: 38423048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of variation in cancer registration practice on observed international cancer survival differences between International Cancer Benchmarking Partnership (ICBP) jurisdictions.
    Eden M; Harrison S; Griffin M; Lambe M; Pettersson D; Gavin A; Brewster DH; Lin Y; Johannesen TB; Milne RL; Farrugia H; Nishri D; King MJ; Huws DW; Warlow J; Turner D; Earle CC; Peake M; Rashbass J
    Cancer Epidemiol; 2019 Feb; 58():184-192. PubMed ID: 30639877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of radiotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study.
    McPhail S; Barclay ME; Swann R; Johnson SA; Alvi R; Barisic A; Bucher O; Creighton N; Denny CA; Dewar RA; Donnelly DW; Dowden JJ; Downie L; Finn N; Gavin AT; Habbous S; Huws DW; Kumar SE; May L; McClure CA; Morrison DS; Møller B; Musto G; Nilssen Y; Saint-Jacques N; Sarker S; Shack L; Tian X; Thomas RJ; Wang H; Woods RR; You H; Zhang B; Lyratzopoulos G;
    Lancet Oncol; 2024 Mar; 25(3):352-365. PubMed ID: 38423049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparability of stage data in cancer registries in six countries: lessons from the International Cancer Benchmarking Partnership.
    Walters S; Maringe C; Butler J; Brierley JD; Rachet B; Coleman MP
    Int J Cancer; 2013 Feb; 132(3):676-85. PubMed ID: 22623157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The International Cancer Benchmarking Partnership: an international collaboration to inform cancer policy in Australia, Canada, Denmark, Norway, Sweden and the United Kingdom.
    Butler J; Foot C; Bomb M; Hiom S; Coleman M; Bryant H; Vedsted P; Hanson J; Richards M;
    Health Policy; 2013 Sep; 112(1-2):148-55. PubMed ID: 23693117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007.
    Walters S; Maringe C; Coleman MP; Peake MD; Butler J; Young N; Bergström S; Hanna L; Jakobsen E; Kölbeck K; Sundstrøm S; Engholm G; Gavin A; Gjerstorff ML; Hatcher J; Johannesen TB; Linklater KM; McGahan CE; Steward J; Tracey E; Turner D; Richards MA; Rachet B;
    Thorax; 2013 Jun; 68(6):551-64. PubMed ID: 23399908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK.
    Lachmann P
    Lancet; 2011 Apr; 377(9772):1149; author reply 1149-50. PubMed ID: 21459202
    [No Abstract]   [Full Text] [Related]  

  • 15. An International Consensus on Actions to Improve Lung Cancer Survival: A Modified Delphi Method Among Clinical Experts in the International Cancer Benchmarking Partnership.
    Lynch C; Harrison S; Butler J; Baldwin DR; Dawkins P; van der Horst J; Jakobsen E; McAleese J; McWilliams A; Redmond K; Swaminath A; Finley CJ
    Cancer Control; 2022; 29():10732748221119354. PubMed ID: 36269109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study.
    Araghi M; Fidler-Benaoudia M; Arnold M; Rutherford M; Bardot A; Ferlay J; Bucher O; De P; Engholm G; Gavin A; Kozie S; Little A; Møller B; St Jacques N; Tervonen H; Walsh P; Woods R; O'Connell DL; Baldwin D; Elwood M; Siesling S; Bray F; Soerjomataram I; ; ; ; ;
    Thorax; 2022 Apr; 77(4):378-390. PubMed ID: 34282033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic pathways for breast cancer in 10 International Cancer Benchmarking Partnership (ICBP) jurisdictions: an international comparative cohort study based on questionnaire and registry data.
    Vedsted P; Weller D; Zalounina Falborg A; Jensen H; Kalsi J; Brewster D; Lin Y; Gavin A; Barisic A; Grunfeld E; Lambe M; Malmberg M; Turner D; Harland E; Hawryluk B; Law RJ; Neal RD; White V; Bergin R; Harrison S; Menon U; ;
    BMJ Open; 2022 Dec; 12(12):e059669. PubMed ID: 36521881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The age-adjusted Charlson comorbidity index is a better predictor of survival in operated lung cancer patients than the Charlson and Elixhauser comorbidity indices.
    Yang CC; Fong Y; Lin LC; Que J; Ting WC; Chang CL; Wu HM; Ho CH; Wang JJ; Huang CI
    Eur J Cardiothorac Surg; 2018 Jan; 53(1):235-240. PubMed ID: 29106506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership.
    Maringe C; Walters S; Butler J; Coleman MP; Hacker N; Hanna L; Mosgaard BJ; Nordin A; Rosen B; Engholm G; Gjerstorff ML; Hatcher J; Johannesen TB; McGahan CE; Meechan D; Middleton R; Tracey E; Turner D; Richards MA; Rachet B;
    Gynecol Oncol; 2012 Oct; 127(1):75-82. PubMed ID: 22750127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five ways to improve international comparisons of cancer survival: lessons learned from ICBP SURVMARK-2.
    Andersson TM; Myklebust TÅ; Rutherford MJ; Møller B; Arnold M; Soerjomataram I; Bray F; Parkin DM; Lambert PC
    Br J Cancer; 2022 May; 126(8):1224-1228. PubMed ID: 35058590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.